{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:16:00Z","timestamp":1789524960182,"version":"build-2803163510"},"reference-count":180,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["16GRNT26430041"],"award-info":[{"award-number":["16GRNT26430041"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s00011-020-01382-6","type":"journal-article","created":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T11:04:12Z","timestamp":1595415852000},"page":"975-988","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":86,"title":["The role of interferon-\u03b3 in cardiovascular disease: an update"],"prefix":"10.1007","volume":"69","author":[{"given":"Ailin","family":"Elyasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iryna","family":"Voloshyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lora J.","family":"Kasselman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Behbodikhah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"De Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4478-2441","authenticated-orcid":false,"given":"Allison B.","family":"Reiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,22]]},"reference":[{"key":"1382_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2019.3891","author":"Y Chen","year":"2019","unstructured":"Chen Y, Freedman ND, Albert PS, Huxley RR, Shiels MS, Withrow DR, et al. Association of cardiovascular disease with premature mortality in the United States. JAMA Cardiol. 2019. https:\/\/doi.org\/10.1001\/jamacardio.2019.3891.","journal-title":"JAMA Cardiol."},{"key":"1382_CR2","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","volume":"139","author":"EJ Benjamin","year":"2019","unstructured":"Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart disease and stroke statistics-2019 update: a report from the American heart association. Circulation. 2019;139:e56\u2013e528. https:\/\/doi.org\/10.1161\/CIR.0000000000000659.","journal-title":"Circulation"},{"key":"1382_CR3","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.immuni.2019.03.007","volume":"50","author":"JW Williams","year":"2019","unstructured":"Williams JW, Huang LH, Randolph GJ. Cytokine circuits in cardiovascular disease. Immunity. 2019;50:941\u201354. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.007.","journal-title":"Immunity"},{"key":"1382_CR4","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.4155\/fmc-2016-0072","volume":"8","author":"JW Moss","year":"2016","unstructured":"Moss JW, Ramji DP. Cytokines: roles in atherosclerosis disease progression and potential therapeutic targets. Future Med Chem. 2016;8:1317\u201330. https:\/\/doi.org\/10.4155\/fmc-2016-0072.","journal-title":"Future Med Chem"},{"key":"1382_CR5","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1056\/nejm199007263230405","volume":"323","author":"B Levine","year":"1990","unstructured":"Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236\u201341. https:\/\/doi.org\/10.1056\/nejm199007263230405.","journal-title":"N Engl J Med"},{"key":"1382_CR6","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/BF01606532","volume":"423","author":"H Kishikawa","year":"1993","unstructured":"Kishikawa H, Shimokama T, Watanabe T. Localization of T lymphocytes and macrophages expressing IL-1, IL-2 receptor, IL-6 and TNF in human aortic intima. Role of cell-mediated immunity in human atherogenesis. Virchows Arch A Pathol Anat Histopathol. 1993;423:433\u201342. https:\/\/doi.org\/10.1007\/BF01606532.","journal-title":"Virchows Arch A Pathol Anat Histopathol."},{"key":"1382_CR7","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2017.1336227","author":"PV Tilstam","year":"2017","unstructured":"Tilstam PV, Qi D, Leng L, Young L, Bucala R. MIF family cytokines in cardiovascular diseases and prospects for precision-based therapeutics. Expert Opin Ther Targets. 2017. https:\/\/doi.org\/10.1080\/14728222.2017.1336227.","journal-title":"Expert Opin Ther Targets."},{"key":"1382_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/bs.acc.2017.06.004","volume":"82","author":"H Mirzaei","year":"2017","unstructured":"Mirzaei H, Ferns GA, Avan A, Mobarhan MG. Cytokines and microRNA in coronary artery disease. Adv Clin Chem. 2017;82:47\u201370. https:\/\/doi.org\/10.1016\/bs.acc.2017.06.004.","journal-title":"Adv Clin Chem"},{"key":"1382_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cyto.2017.04.012","volume":"98","author":"EY Kim","year":"2017","unstructured":"Kim EY, Moudgil KD. Immunomodulation of autoimmune arthritis by pro-inflammatory cytokines. Cytokine. 2017;98:87\u201396. https:\/\/doi.org\/10.1016\/j.cyto.2017.04.012.","journal-title":"Cytokine"},{"key":"1382_CR10","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jbiotec.2016.10.022","volume":"240","author":"A Razaghi","year":"2016","unstructured":"Razaghi A, Owens L, Heimann K. Review of the recombinant human interferon gamma as an immunotherapeutic: impacts of production platforms and glycosylation. J Biotechnol. 2016;240:48\u201360. https:\/\/doi.org\/10.1016\/j.jbiotec.2016.10.022.","journal-title":"J Biotechnol"},{"key":"1382_CR11","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/366583a0","volume":"366","author":"O Silvennoinen","year":"1993","unstructured":"Silvennoinen O, Ihle JN, Schlessinger J, Levy DE. Interferon-induced nuclear signaling by Jak protein tyrosine kinases. Nature. 1993;366:583\u20135.","journal-title":"Nature"},{"key":"1382_CR12","doi-asserted-by":"publisher","first-page":"D1040","DOI":"10.1093\/nar\/gks1215","volume":"41","author":"I Rusinova","year":"2013","unstructured":"Rusinova I, Forster S, Yu S, Kannan A, Masse M, Cumming H, et al. Interferome v2.0: an updated database of annotated interferon-regulated genes. Nucleic Acids Res. 2013;41:D1040\u2013D10461046. https:\/\/doi.org\/10.1093\/nar\/gks1215.","journal-title":"Nucleic Acids Res."},{"key":"1382_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.tcm.2013.06.003","volume":"24","author":"I Voloshyna","year":"2014","unstructured":"Voloshyna I, Littlefield MJ, Reiss AB. Atherosclerosis and interferon-\u03b3: new insights and therapeutic targets. Trends Cardiovasc Med. 2014;24:45\u201351. https:\/\/doi.org\/10.1016\/j.tcm.2013.06.003.","journal-title":"Trends Cardiovasc Med"},{"key":"1382_CR14","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.immuni.2013.06.009","volume":"38","author":"P Libby","year":"2013","unstructured":"Libby P, Lichtman AH, Hansson GK. Immune effector mechanisms implicated in atherosclerosis: from mice to humans. Immunity. 2013;38:1092\u2013104. https:\/\/doi.org\/10.1016\/j.immuni.2013.06.009.","journal-title":"Immunity"},{"key":"1382_CR15","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/nature09753","volume":"470","author":"O Harismendy","year":"2011","unstructured":"Harismendy O, Notani D, Song X, Rahim NG, Tanasa B, Heintzman N, et al. 9p21 DNA variants associated with coronary artery disease impair interferon-gamma signalling response. Nature. 2011;470:264\u20138. https:\/\/doi.org\/10.1038\/nature09753.","journal-title":"Nature"},{"key":"1382_CR16","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1160\/TH11-05-0321","volume":"106","author":"DF Ketelhuth","year":"2011","unstructured":"Ketelhuth DF, Hansson GK. Cellular immunity, low-density lipoprotein and atherosclerosis: break of tolerance in the artery wall. Thromb Haemost. 2011;106:779\u201386. https:\/\/doi.org\/10.1160\/TH11-05-0321.","journal-title":"Thromb Haemost"},{"key":"1382_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1080\/14740338.2018.1394455","volume":"17","author":"S Bellosta","year":"2018","unstructured":"Bellosta S, Corsini A. Statin drug interactions and related adverse reactions: an update. Expert Opin Drug Saf. 2018;17:25\u201337. https:\/\/doi.org\/10.1080\/14740338.2018.1394455.","journal-title":"Expert Opin Drug Saf"},{"key":"1382_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11883-019-0780-z","volume":"21","author":"R Carmena","year":"2019","unstructured":"Carmena R, Betteridge DJ. Diabetogenic action of statins: mechanisms. Curr Atheroscler Rep. 2019;21:23. https:\/\/doi.org\/10.1007\/s11883-019-0780-z.","journal-title":"Curr Atheroscler Rep"},{"key":"1382_CR19","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1515\/aiht-2017-68-2994","volume":"68","author":"B Karahalil","year":"2017","unstructured":"Karahalil B, Hare E, Ko\u00e7 G, Uslu \u0130, \u015eent\u00fcrk K, \u00d6zkan Y. Hepatotoxicity associated with statins. Arh Hig Rada Toksikol. 2017;68:254\u201360. https:\/\/doi.org\/10.1515\/aiht-2017-68-2994.","journal-title":"Arh Hig Rada Toksikol"},{"issue":"Suppl 3","key":"1382_CR20","doi-asserted-by":"crossref","first-page":"S327","DOI":"10.33549\/physiolres.932865","volume":"63","author":"M Vrablik","year":"2014","unstructured":"Vrablik M, Zlatohlavek L, Stulc T, Adamkova V, Prusikova M, Schwarzova L, et al. Statin-associated myopathy: from genetic predisposition to clinical management. Physiol Res. 2014;63(Suppl 3):S327\u2013S334334.","journal-title":"Physiol Res"},{"key":"1382_CR21","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.plipres.2011.04.002","volume":"50","author":"JE McLaren","year":"2011","unstructured":"McLaren JE, Michael DR, Ashlin TG, Ramji DP. Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. Prog Lipid Res. 2011;50:331\u201347. https:\/\/doi.org\/10.1016\/j.plipres.2011.04.002.","journal-title":"Prog Lipid Res"},{"key":"1382_CR22","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1136\/ard.2010.136762","volume":"70","author":"MA Petri","year":"2011","unstructured":"Petri MA, Kiani AN, Post W, Christopher-Stine L, Magder LS. Lupus atherosclerosis prevention study (LAPS). Ann Rheum Dis. 2011;70:760\u20135. https:\/\/doi.org\/10.1136\/ard.2010.136762.","journal-title":"Ann Rheum Dis"},{"key":"1382_CR23","doi-asserted-by":"publisher","first-page":"E514","DOI":"10.3390\/medicina55090514","volume":"55","author":"AB Reiss","year":"2019","unstructured":"Reiss AB, Arain HA, Kasselman LJ, Renna HA, Zhen J, Voloshyna I, et al. Human lupus plasma pro-atherogenic effects on cultured macrophages are not mitigated by statin therapy: a mechanistic LAPS substudy. Medicina (Kaunas). 2019;55:E514. https:\/\/doi.org\/10.3390\/medicina55090514.","journal-title":"Medicina (Kaunas)."},{"key":"1382_CR24","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s11883-014-0435-z","volume":"16","author":"E Golia","year":"2014","unstructured":"Golia E, Limongelli G, Natale F, Fimiani F, Maddaloni V, Pariggiano I, et al. Inflammation and cardiovascular disease: from pathogenesis to therapeutic target. Curr Atheroscler Rep. 2014;16:435. https:\/\/doi.org\/10.1007\/s11883-014-0435-z.","journal-title":"Curr Atheroscler Rep"},{"key":"1382_CR25","doi-asserted-by":"publisher","first-page":"154","DOI":"10.5493\/wjem.v5.i3.154","volume":"5","author":"JW Moss","year":"2015","unstructured":"Moss JW, Ramji DP. Interferon-\u03b3: promising therapeutic target in atherosclerosis. World J Exp Med. 2015;5:154\u20139. https:\/\/doi.org\/10.5493\/wjem.v5.i3.154.","journal-title":"World J Exp Med"},{"key":"1382_CR26","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/s0969-2126(00)00184-2","volume":"8","author":"D Thiel","year":"2000","unstructured":"Thiel D, le Du MH, Walter R, D\u2019Arcy A, Ch\u00e8ne C, Fountoulakis M, et al. Observation of an unexpected third receptor molecule in the crystal structure of human interferon-\u03b3 receptor complex. Structure. 2000;8:927\u201336. https:\/\/doi.org\/10.1016\/s0969-2126(00)00184-2.","journal-title":"Structure"},{"key":"1382_CR27","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1126\/science.1902591","volume":"252","author":"S Ealick","year":"1991","unstructured":"Ealick S, Cook WJ, Vijay-Kumar S, Carson M, Nagabhushan TL, Trotta PP, Bugg CE. Three-dimensional structure of recombinant human interferon-\u03b3. Science. 1991;252:698\u2013702. https:\/\/doi.org\/10.1126\/science.1902591.","journal-title":"Science"},{"key":"1382_CR28","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/nri1604","volume":"5","author":"LC Platanias","year":"2005","unstructured":"Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5:375\u201386. https:\/\/doi.org\/10.1038\/nri1604.","journal-title":"Nat Rev Immunol"},{"key":"1382_CR29","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.0105-2896.2004.00204.x","volume":"202","author":"S Pestka","year":"2004","unstructured":"Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev. 2004;202:8\u201332. https:\/\/doi.org\/10.1111\/j.0105-2896.2004.00204.x.","journal-title":"Immunol Rev"},{"key":"1382_CR30","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ygeno.2004.03.003","volume":"84","author":"MP Hardy","year":"2004","unstructured":"Hardy MP, Owczarek CM, Jermiin LS, Ejdeb\u00e4ck M, Hertzog PJ. Characterization of the type I interferon locus and identification of novel genes. Genomics. 2004;84:331\u201345.","journal-title":"Genomics"},{"key":"1382_CR31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.cytogfr.2009.02.006","volume":"20","author":"R Savan","year":"2009","unstructured":"Savan R, Ravichandran S, Collins JR, Sakai M, Young HA. Structural conservation of interferon gamma among vertebrates. Cytokine Growth Factor Rev. 2009;20:115\u201324. https:\/\/doi.org\/10.1016\/j.cytogfr.2009.02.006.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1382_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/s0003-9861(03)00113-9","volume":"413","author":"G Nacheva","year":"2003","unstructured":"Nacheva G, Todorova K, Boyanova M, Berzal-Herranz A, Karshikoff A, Ivanov I. Human interferon gamma: significance of the C-terminal flexible domain for its biological activity. Arch Biochem Biophys. 2003;413:91\u20138. https:\/\/doi.org\/10.1016\/s0003-9861(03)00113-9.","journal-title":"Arch Biochem Biophys"},{"key":"1382_CR33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00894-019-4013-8","volume":"25","author":"E Lilkova","year":"2019","unstructured":"Lilkova E, Petkov P, Ilieva N, Krachmarova E, Nacheva G, Litov L. Molecular modeling of the effects of glycosylation on the structure and dynamics of human interferon-gamma. J Mol Model. 2019;25:127. https:\/\/doi.org\/10.1007\/s00894-019-4013-8.","journal-title":"J Mol Model"},{"key":"1382_CR34","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1042\/bj3030831","volume":"303","author":"T Sareneva","year":"1994","unstructured":"Sareneva T, Pirhonen J, Cantell K, Kalkkinent N, Julkunen L. Role of N-glycosylation in the synthesis, dimerization and secretion of human interferon-\u03b3. Biochem J. 1994;303:831\u201340. https:\/\/doi.org\/10.1042\/bj3030831.","journal-title":"Biochem J"},{"key":"1382_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1042\/bj3080009","volume":"308","author":"T Sareneva","year":"1995","unstructured":"Sareneva T, Pirhonen J, Cantell K, Julkunen L. N-glycosylation of human interferon-\u03b3: glycans at Asn-25 are critical for protease resistance. Biochem J. 1995;308:9\u201314.","journal-title":"Biochem J"},{"key":"1382_CR36","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41586-019-0988-7","volume":"567","author":"JL Mendoza","year":"2019","unstructured":"Mendoza JL, Escalante NK, Jude KM, Sotolongo Bellon J, Su L, Horton TM, et al. Structure of the IFN\u03b3 receptor complex guides design of biased agonists. Nature. 2019;567:56\u201360. https:\/\/doi.org\/10.1038\/s41586-019-0988-7.","journal-title":"Nature"},{"key":"1382_CR37","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1002\/eji.201646768","volume":"47","author":"J Pirault","year":"2017","unstructured":"Pirault J, Polyzos KA, Petri MH, Ketelhuth DFJ, B\u00e4ck M, Hansson GK. The inflammatory cytokine interferon-gamma inhibits sortilin-1 expression in hepatocytes via the JAK\/STAT pathway. Eur J Immunol. 2017;47:1918\u201324. https:\/\/doi.org\/10.1002\/eji.201646768.","journal-title":"Eur J Immunol"},{"key":"1382_CR38","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/978-3-540-71329-6_6","volume":"316","author":"HA Young","year":"2007","unstructured":"Young HA, Bream JH. IFN-gamma: recent advances in understanding regulation of expression, biological functions, and clinical applications. Curr Top Microbiol Immunol. 2007;316:97\u2013117. https:\/\/doi.org\/10.1007\/978-3-540-71329-6_6.","journal-title":"Curr Top Microbiol Immunol"},{"key":"1382_CR39","doi-asserted-by":"publisher","first-page":"6508","DOI":"10.1128\/MCB.17.11.6508","volume":"17","author":"J Chung","year":"1997","unstructured":"Chung J, Uchida E, Grammer TC, Blenis J. STAT3 Serine Phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol. 1997;17:6508\u201316.","journal-title":"Mol Cell Biol"},{"key":"1382_CR40","doi-asserted-by":"publisher","first-page":"e59531","DOI":"10.1371\/journal.pone.0059531","volume":"8","author":"M Simanski","year":"2013","unstructured":"Simanski M, Rademacher F, Schr\u00f6der L, Schumacher HM, Gl\u00e4ser R, Harder J. IL-17A and IFN-\u03b3 synergistically induce RNase 7 expression via STAT3 in primary keratinocytes. PLoS ONE. 2013;8:e59531. https:\/\/doi.org\/10.1371\/journal.pone.0059531.","journal-title":"PLoS ONE"},{"key":"1382_CR41","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/978-3-540-71329-6_7","volume":"316","author":"AH van Boxel-Dezaire","year":"2007","unstructured":"van Boxel-Dezaire AH, Stark GR. Cell type-specific signaling in response to interferon-gamma. Curr Top Microbiol Immunol. 2007;316:119\u201354. https:\/\/doi.org\/10.1007\/978-3-540-71329-6_7.","journal-title":"Curr Top Microbiol Immunol"},{"key":"1382_CR42","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.plipres.2018.12.002","volume":"73","author":"XH Yu","year":"2019","unstructured":"Yu XH, Zhang DW, Zheng XL, Tang CK. Cholesterol transport system: an integrated cholesterol transport model involved in atherosclerosis. Prog Lipid Res. 2019;73:65\u201391. https:\/\/doi.org\/10.1016\/j.plipres.2018.12.002.","journal-title":"Prog Lipid Res"},{"issue":"1","key":"1382_CR43","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/jcmm.12689","volume":"20","author":"DA Chistiakov","year":"2016","unstructured":"Chistiakov DA, Bobryshev YV, Orekhov AN. Macrophage-mediated cholesterol handling in atherosclerosis. J Cell Mol Med. 2016;20(1):17\u201328. https:\/\/doi.org\/10.1111\/jcmm.12689.","journal-title":"J Cell Mol Med"},{"key":"1382_CR44","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.1038\/emm.2014.38","volume":"46","author":"YM Park","year":"2014","unstructured":"Park YM. CD36, a scavenger receptor implicated in atherosclerosis. Exp Mol Med. 2014;46:e99. https:\/\/doi.org\/10.1038\/emm.2014.38.","journal-title":"Exp Mol Med"},{"key":"1382_CR45","unstructured":"Reiss AB, Glass AD. CD36 and ScR-A: scavenger receptors that mediate uptake of oxidized low-density lipoprotein and foam cell formation. In: Reiss AB, Carsons S, Cronstein BN, editors. Proteins involved in the pathogenesis of atherosclerosis. Research Signpost; 2006. pp. 1\u201312."},{"key":"1382_CR46","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1161\/CIRCULATIONAHA.105.540583","volume":"114","author":"AM Aslanian","year":"2006","unstructured":"Aslanian AM, Charo IF. Targeted disruption of the scavenger receptor and chemokine CXCL16 accelerates atherosclerosis. Circulation. 2006;114:583\u201390. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.105.540583.","journal-title":"Circulation"},{"key":"1382_CR47","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1096\/fj.13-233791","volume":"28","author":"L Zurkinden","year":"2014","unstructured":"Zurkinden L, Solc\u00e0 C, V\u00f6geli IA, Vogt B, Ackermann D, Erickson SK, et al. Effect of Cyp27A1 gene dosage on atherosclerosis development in ApoE-knockout mice. FASEB J. 2014;28:1198\u2013209. https:\/\/doi.org\/10.1096\/fj.13-233791.","journal-title":"FASEB J"},{"key":"1382_CR48","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.mce.2012.07.013","volume":"368","author":"PS Pannu","year":"2013","unstructured":"Pannu PS, Allahverdian S, Francis GA. Oxysterol generation and liver X receptor-dependent reverse cholesterol transport: not all roads lead to Rome. Mol Cell Endocrinol. 2013;368:99\u2013107. https:\/\/doi.org\/10.1016\/j.mce.2012.07.013.","journal-title":"Mol Cell Endocrinol"},{"key":"1382_CR49","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.plipres.2011.02.001","volume":"50","author":"I Voloshyna","year":"2011","unstructured":"Voloshyna I, Reiss AB. The ABC transporters in lipid flux and atherosclerosis. Prog Lipid Res. 2011;50:213\u201324. https:\/\/doi.org\/10.1016\/j.plipres.2011.02.001.","journal-title":"Prog Lipid Res"},{"key":"1382_CR50","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1194\/jlr.M700274-JLR200","volume":"48","author":"MP Adorni","year":"2007","unstructured":"Adorni MP, Zimetti F, Billheimer JT, Wang N, Rader DJ, Phillips MC, Rothblat GH. The roles of different pathways in the release of cholesterol from macrophages. J Lipid Res. 2007;48:2453\u201362. https:\/\/doi.org\/10.1194\/jlr.M700274-JLR200.","journal-title":"J Lipid Res"},{"key":"1382_CR51","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1161\/01.atv.21.5.825","volume":"21","author":"T Grewal","year":"2001","unstructured":"Grewal T, Priceputu E, Davignon J, Bernier L. Identification of a \u03b3-interferon\u2013responsive element in the promoter of the human macrophage scavenger receptor A gene. Arterioscler Thromb Vasc Biol. 2001;21:825\u201331. https:\/\/doi.org\/10.1161\/01.atv.21.5.825.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1382_CR52","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1172\/JCI115718","volume":"89","author":"Y Geng","year":"1992","unstructured":"Geng Y, Hansson GK. Interferon-gamma inhibits scavenger receptor expression and foam cell formation in human monocyte derived macrophages. J Clin Invest. 1992;89:1322\u201330. https:\/\/doi.org\/10.1172\/JCI115718.","journal-title":"J Clin Invest"},{"key":"1382_CR53","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1161\/01.atv.18.8.1350","volume":"18","author":"T Nakagawa","year":"1998","unstructured":"Nakagawa T, Nozaki S, Nishida M, Yakub JM, Tomiyama Y, Nakata A, et al. Oxidized LDL increases and interferon-gamma decreases expression of CD36 in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol. 1998;18:1350\u20137. https:\/\/doi.org\/10.1161\/01.atv.18.8.1350.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1382_CR54","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0022-2275(20)32076-9","volume":"41","author":"CG Panousis","year":"2000","unstructured":"Panousis CG, Zuckerman SH. Regulation of cholesterol distribution in macrophage-derived foam cells by interferon-\u03b3. J Lipid Res. 2000;41:75\u201383.","journal-title":"J Lipid Res"},{"issue":"4","key":"1382_CR55","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1161\/01.ATV.0000124102.11472.36","volume":"24","author":"DM Wuttge","year":"2004","unstructured":"Wuttge DM, Zhou X, Sheikine Y, W\u00e5gs\u00e4ter D, Stemme V, Hedin U, et al. CXCL16\/SR-PSOX is an interferon-gamma-regulated chemokine and scavenger receptor expressed in atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2004;24(4):750\u20135. https:\/\/doi.org\/10.1161\/01.ATV.0000124102.11472.36.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1382_CR56","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.bbrc.2004.10.160","volume":"325","author":"D W\u00e5gs\u00e4ter","year":"2004","unstructured":"W\u00e5gs\u00e4ter D, Olofsson PS, Norgren L, Stenberg B, Sirsj\u00f6 A. The chemokine and scavenger receptor CXCL16\/SR-PSOX is expressed in human vascular smooth muscle cells and is induced by interferon gamma. Biochem Biophys Res Commun. 2004;325:1187\u201393. https:\/\/doi.org\/10.1016\/j.bbrc.2004.10.160.","journal-title":"Biochem Biophys Res Commun"},{"key":"1382_CR57","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1161\/CIRCULATIONAHA.108.806877","volume":"119","author":"AM Jansson","year":"2009","unstructured":"Jansson AM, Aukrust P, Ueland T, Smith C, Omland T, Hartford M, et al. Soluble CXCL16 predicts long-term mortality in acute coronary syndromes. Circulation. 2009;119:3181\u20138. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.806877.","journal-title":"Circulation"},{"key":"1382_CR58","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.atherosclerosis.2015.11.022","volume":"244","author":"LE Laugsand","year":"2016","unstructured":"Laugsand LE, \u00c5svold BO, Vatten LJ, Janszky I, Platou C, Michelsen AE, et al. Soluble CXCL16 and risk of myocardial infarction: the HUNT study in Norway. Atherosclerosis. 2016;244:188\u201394. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.11.022.","journal-title":"Atherosclerosis"},{"key":"1382_CR59","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/S0022-2275(20)31518-2","volume":"42","author":"AB Reiss","year":"2001","unstructured":"Reiss AB, Awadallah NW, Malhotra S, Montesinos MC, Chan ES, Javitt NB, et al. Immune complexes and IFN-gamma decrease cholesterol 27-hydroxylase in human arterial endothelium and macrophages. J Lipid Res. 2001;42:1913\u201322.","journal-title":"J Lipid Res"},{"key":"1382_CR60","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/qjmed\/hci136","volume":"98","author":"R Ohashi","year":"2005","unstructured":"Ohashi R, Mu H, Wang X, Yao Q, Chen C. Reverse cholesterol transport and cholesterol efflux in atherosclerosis. QJM. 2005;98:845\u201356. https:\/\/doi.org\/10.1093\/qjmed\/hci136.","journal-title":"QJM"},{"key":"1382_CR61","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.atherosclerosis.2008.07.029","volume":"203","author":"XR Hao","year":"2009","unstructured":"Hao XR, Cao DL, Hu YW, Li XX, Liu XH, Xiao J, et al. IFN-gamma down-regulates ABCA1 expression by inhibiting LXRalpha in a JAK\/STAT signaling pathway-dependent manner. Atherosclerosis. 2009;203:417\u201328. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2008.07.029.","journal-title":"Atherosclerosis"},{"key":"1382_CR62","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1161\/01.atv.0000018287.03856.dd","volume":"22","author":"XQ Wang","year":"2002","unstructured":"Wang XQ, Panousis CG, Alfaro ML, Evans GF, Zuckerman SH. Interferon-\u03b3\u2013mediated downregulation of cholesterol efflux and ABC1 expression is by the stat1 pathway. Arterioscler Thromb Vasc Biol. 2002;22:e5\u20139. https:\/\/doi.org\/10.1161\/01.atv.0000018287.03856.dd.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1382_CR63","doi-asserted-by":"publisher","first-page":"6520","DOI":"10.4049\/jimmunol.1201393","volume":"190","author":"M Pascual-Garc\u00eda","year":"2013","unstructured":"Pascual-Garc\u00eda M, Ru\u00e9 L, Le\u00f3n T, Julve J, Carb\u00f3 JM, Matalonga J, et al. Reciprocal negative cross-talk between liver x receptors (LXRs) and STAT1: effects on IFN-\u03b3\u2013induced inflammatory responses and LXR-dependent gene expression. J Immunol. 2013;190:6520\u201332. https:\/\/doi.org\/10.4049\/jimmunol.1201393.","journal-title":"J Immunol"},{"key":"1382_CR64","doi-asserted-by":"publisher","first-page":"e0193429","DOI":"10.1371\/journal.pone.0193429","volume":"13","author":"PM Kulling","year":"2018","unstructured":"Kulling PM, Olson KC, Hamele CE, Toro MF, Tan S, Feith DJ, et al. Dysregulation of the IFN-\u03b3-STAT1 signaling pathway in a cell line model of large granular lymphocyte leukemia. PLoS ONE. 2018;13:e0193429. https:\/\/doi.org\/10.1371\/journal.pone.0193429.","journal-title":"PLoS ONE"},{"key":"1382_CR65","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/383787a0","volume":"383","author":"AK Abbas","year":"1996","unstructured":"Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature. 1996;383:787\u201393. https:\/\/doi.org\/10.1038\/383787a0.","journal-title":"Nature"},{"issue":"11","key":"1382_CR66","first-page":"420","volume":"10","author":"AB Reiss","year":"2004","unstructured":"Reiss AB, Patel CA, Rahman MM, Chan ES, Hasneen K, Montesinos MC, et al. Interferon-gamma impedes reverse cholesterol transport and promotes foam cell transformation in THP-1 human monocytes\/macrophages. Med Sci Monit. 2004;10(11):420\u20135.","journal-title":"Med Sci Monit"},{"key":"1382_CR67","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1161\/atvbaha.115.305464","volume":"35","author":"MC Boshuizen","year":"2015","unstructured":"Boshuizen MC, Winther MP. Interferons as essential modulators of atherosclerosis. Arterioscler Thromb Vasc Biol. 2015;35:1579\u201388. https:\/\/doi.org\/10.1161\/atvbaha.115.305464.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1382_CR68","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/s0021-9150(99)00011-8","volume":"145","author":"J Frosteg\u00e5rd","year":"1999","unstructured":"Frosteg\u00e5rd J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis. 1999;145:33\u201343. https:\/\/doi.org\/10.1016\/s0021-9150(99)00011-8.","journal-title":"Atherosclerosis"},{"issue":"2","key":"1382_CR69","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/cei.12477","volume":"179","author":"E Ammirati","year":"2015","unstructured":"Ammirati E, Moroni F, Magnoni M, Camici PG. The role of T and B cells in human atherosclerosis and atherothrombosis. Clin Exp Immunol. 2015;179(2):173\u201387. https:\/\/doi.org\/10.1111\/cei.12477.","journal-title":"Clin Exp Immunol"},{"key":"1382_CR70","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/s1097-2765(01)00239-8","volume":"7","author":"D Zohlnhofer","year":"2001","unstructured":"Zohlnhofer D, Richter T, Neumann F, Nuhrenberg T, Wessely R, Brandl R, et al. Transcriptome analysis reveals a role of interferon-gamma in human neointima formation. Mol Cell. 2001;7:1059\u201369. https:\/\/doi.org\/10.1016\/s1097-2765(01)00239-8.","journal-title":"Mol Cell"},{"key":"1382_CR71","doi-asserted-by":"publisher","first-page":"592","DOI":"10.4049\/jimmunol.178.1.592","volume":"178","author":"H Ranjbaran","year":"2007","unstructured":"Ranjbaran H, Sokol SI, Gallo A, Eid RE, Iakimov AO, D'Alessio A, Kapoor JR, Akhtar S, Howes CJ, Aslan M, Pfau S, Pober JS, Tellides G. An inflammatory pathway of IFN-gamma production in coronary atherosclerosis. J Immunol. 2007;178:592\u2013604. https:\/\/doi.org\/10.4049\/jimmunol.178.1.592.","journal-title":"J Immunol"},{"issue":"2","key":"1382_CR72","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.atherosclerosis.2012.03.016","volume":"222","author":"J George","year":"2012","unstructured":"George J, Schwartzenberg S, Medvedovsky D, Jonas M, Charach G, Afek A, et al. Regulatory T cells and IL-10 levels are reduced in patients with vulnerable coronary plaques. Atherosclerosis. 2012;222(2):519\u201323. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2012.03.016.","journal-title":"Atherosclerosis"},{"key":"1382_CR73","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1002\/humu.21484","volume":"32","author":"J Manry","year":"2011","unstructured":"Manry J, Laval G, Patin E, Fornarino S, Tichit M, Bouchier C, et al. Evolutionary genetics evidence of an essential, nonredundant role of the IFN-\u03b3 pathway in protective immunity. Hum Mutat. 2011;32:633\u201342. https:\/\/doi.org\/10.1002\/humu.21484.","journal-title":"Hum Mutat"},{"issue":"6","key":"1382_CR74","doi-asserted-by":"publisher","first-page":"C1337","DOI":"10.1152\/ajpcell.00276.2010","volume":"300","author":"K Sikorski","year":"2011","unstructured":"Sikorski K, Chmielewski S, Przybyl L, Heemann U, Wesoly J, Baumann M, et al. STAT1-mediated signal integration between IFN\u03b3 and LPS leads to increased EC and SMC activation and monocyte adhesion. Am J Physiol Cell Physiol. 2011;300(6):C1337\u2013C13441344. https:\/\/doi.org\/10.1152\/ajpcell.00276.2010.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"4","key":"1382_CR75","doi-asserted-by":"publisher","first-page":"241","DOI":"10.4161\/jkst.22469","volume":"1","author":"K Sikorski","year":"2012","unstructured":"Sikorski K, Chmielewski S, Olejnik A, Wesoly JZ, Heemann U, Baumann M, et al. STAT1 as a central mediator of IFN\u03b3 and TLR4 signal integration in vascular dysfunction. JAKSTAT. 2012;1(4):241\u20139. https:\/\/doi.org\/10.4161\/jkst.22469.","journal-title":"JAKSTAT"},{"key":"1382_CR76","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cca.2014.12.007","volume":"441","author":"XH Yu","year":"2015","unstructured":"Yu XH, Zhang J, Zheng XL, Yang YH, Tang CK. Interferon-\u03b3 in foam formation and progression of atherosclerosis. Clin Chim Acta. 2015;441:33\u201343. https:\/\/doi.org\/10.1016\/j.cca.2014.12.007.","journal-title":"Clin Chim Acta"},{"issue":"12","key":"1382_CR77","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1002\/art.24040","volume":"58","author":"AB Reiss","year":"2008","unstructured":"Reiss AB, Carsons SE, Anwar K, Rao S, Edelman SD, Zhang H, et al. Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte\/macrophages. Arthritis Rheum. 2008;58(12):3675\u201383. https:\/\/doi.org\/10.1002\/art.24040.","journal-title":"Arthritis Rheum"},{"key":"1382_CR78","doi-asserted-by":"publisher","first-page":"001","DOI":"10.23937\/2378-3672\/1410001","volume":"1","author":"MJ Littlefield","year":"2014","unstructured":"Littlefield MJ, Teboul I, Voloshyna I, Reiss AB. Polarization of human THP-1 macrophages: link between adenosine receptors, inflammation and lipid accumulation. Int J Immunol Immunother. 2014;1:001. https:\/\/doi.org\/10.23937\/2378-3672\/1410001.","journal-title":"Int J Immunol Immunother"},{"key":"1382_CR79","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.immuni.2017.09.008","volume":"47","author":"I Tabas","year":"2017","unstructured":"Tabas I, Lichtman AH. Monocyte-macrophages and T cells in atherosclerosis. Immunity. 2017;47:621\u201334. https:\/\/doi.org\/10.1016\/j.immuni.2017.09.008.","journal-title":"Immunity"},{"key":"1382_CR80","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1590\/s0074-02762005000900024","volume":"1001","author":"LK Teixeira","year":"2005","unstructured":"Teixeira LK, Fonseca BP, Barboza BA, Viola JP. The role of interferon-g on immune and allergic responses. Mem Inst Oswaldo Cruz. 2005;1001:137\u201344. https:\/\/doi.org\/10.1590\/s0074-02762005000900024.","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"1382_CR81","doi-asserted-by":"publisher","first-page":"5472","DOI":"10.4049\/jimmunol.165.10.5472","volume":"165","author":"EY So","year":"2000","unstructured":"So EY, Park HH, Lee CE. IFN-\u03b3 and IFN-\u03b1 posttranscriptionally down-regulate the IL-4-induced IL-4 receptor gene expression. J Immunol. 2000;165:5472\u20139. https:\/\/doi.org\/10.4049\/jimmunol.165.10.5472.","journal-title":"J Immunol"},{"issue":"3","key":"1382_CR82","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1161\/ATVBAHA.112.300871","volume":"33","author":"D Engelbertsen","year":"2013","unstructured":"Engelbertsen D, Andersson L, Ljungcrantz I, Wigren M, Hedblad B, Nilsson J, et al. T-helper 2 immunity is associated with reduced risk of myocardial infarction and stroke. Arterioscler Thromb Vasc Biol. 2013;33(3):637\u201344. https:\/\/doi.org\/10.1161\/ATVBAHA.112.300871.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1382_CR83","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/nri1733","volume":"5","author":"S Gordon","year":"2005","unstructured":"Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5:953\u201364. https:\/\/doi.org\/10.1038\/nri1733.","journal-title":"Nat Rev Immunol"},{"key":"1382_CR84","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ebiom.2018.02.009","volume":"30","author":"F Wang","year":"2018","unstructured":"Wang F, Zhang S, Jeon R, Vuckovic I, Jiang X, Lerman A, et al. Interferon gamma induces reversible metabolic reprogramming of M1 macrophages to sustain cell viability and pro-inflammatory activity. EBioMedicine. 2018;30:303\u201316. https:\/\/doi.org\/10.1016\/j.ebiom.2018.02.009.","journal-title":"EBioMedicine"},{"key":"1382_CR85","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s40169-014-0042-1","volume":"3","author":"HJ Medbury","year":"2014","unstructured":"Medbury HJ, Williams H, Fletcher JP. Clinical significance of macrophage phenotypes in cardiovascular disease. Clin Transl Med. 2014;3:63. https:\/\/doi.org\/10.1186\/s40169-014-0042-1.","journal-title":"Clin Transl Med"},{"key":"1382_CR86","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00418-015-1386-3","volume":"145","author":"MJ Zhang","year":"2016","unstructured":"Zhang MJ, Zhou Y, Chen L, Wang YQ, Wang X, Pi Y, et al. An overview of potential molecular mechanisms involved in VSMC phenotypic modulation. Histochem Cell Biol. 2016;145:119\u201330. https:\/\/doi.org\/10.1007\/s00418-015-1386-3.","journal-title":"Histochem Cell Biol"},{"key":"1382_CR87","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.atherosclerosis.2005.03.026","volume":"184","author":"PI Morelli","year":"2006","unstructured":"Morelli PI, Martinsson S, Ostergren-Lund\u00e9n G, Frid\u00e9n V, Moses J, Bondjers G, et al. IFN gamma regulates PDGF-receptor alpha expression in macrophages, THP-1 cells, and arterial smooth muscle cells. Atherosclerosis. 2006;184:39\u201347. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2005.03.026.","journal-title":"Atherosclerosis"},{"key":"1382_CR88","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1161\/CIRCRESAHA.107.151068","volume":"101","author":"Y Wang","year":"2007","unstructured":"Wang Y, Bai Y, Qin L, Zhang P, Yi T, Teesdale SA, et al. Interferon-gamma induces human vascular smooth muscle cell proliferation and intimal expansion by phosphatidylinositol 3-kinase dependent mammalian target of rapamycin raptor complex 1 activation. Circ Res. 2007;101:560\u20139. https:\/\/doi.org\/10.1161\/CIRCRESAHA.107.151068.","journal-title":"Circ Res"},{"key":"1382_CR89","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/35003221","volume":"403","author":"G Tellides","year":"2000","unstructured":"Tellides G, Tereb DA, Kirkiles-Smith NC, Kim RW, Wilson JH, Schechner JS, et al. Interferon-gamma elicits arteriosclerosis in the absence of leukocytes. Nature. 2000;403:207\u201311. https:\/\/doi.org\/10.1038\/35003221.","journal-title":"Nature"},{"key":"1382_CR90","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.3389\/fimmu.2019.01253","volume":"10","author":"A Piaszyk-Borychowska","year":"2019","unstructured":"Piaszyk-Borychowska A, Sz\u00e9les L, Csermely A, Chiang HC, Weso\u0142y J, Lee CK, et al. Signal integration of IFN-I and IFN-II with TLR4 involves sequential recruitment of STAT1-complexes and NF\u03baB to enhance pro-inflammatory transcription. Front Immunol. 2019;10:1253. https:\/\/doi.org\/10.3389\/fimmu.2019.01253.","journal-title":"Front Immunol"},{"issue":"12","key":"1382_CR91","doi-asserted-by":"publisher","first-page":"e113318","DOI":"10.1371\/journal.pone.0113318","volume":"9","author":"S Chmielewski","year":"2014","unstructured":"Chmielewski S, Olejnik A, Sikorski K, Pelisek J, B\u0142aszczyk K, Aoqui C, et al. STAT1-dependent signal integration between IFN\u03b3 and TLR4 in vascular cells reflect pro-atherogenic responses in human atherosclerosis. PLoS ONE. 2014;9(12):e113318. https:\/\/doi.org\/10.1371\/journal.pone.0113318.","journal-title":"PLoS ONE"},{"key":"1382_CR92","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1161\/CIRCRESAHA.115.306361","volume":"118","author":"MR Bennett","year":"2016","unstructured":"Bennett MR, Sinha S, Owens GK. Vascular smooth muscle cells in atherosclerosis. Circ Res. 2016;118:692\u2013702. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.306361.","journal-title":"Circ Res"},{"key":"1382_CR93","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1038\/nm1102-1257","volume":"8","author":"P Libby","year":"2002","unstructured":"Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med. 2002;8:1257\u201362. https:\/\/doi.org\/10.1038\/nm1102-1257.","journal-title":"Nat Med"},{"key":"1382_CR94","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.atherosclerosis.2012.03.016","volume":"222","author":"J George","year":"2012","unstructured":"George J, Schwartzenberg S, Medvedovsky D, Jonas M, Charach G, Afek A, et al. Regulatory T cells and IL-10 levels are reduced in patients with vulnerable coronary plaques. Atherosclerosis. 2012;222:519\u201323. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2012.03.016.","journal-title":"Atherosclerosis"},{"issue":"2","key":"1382_CR95","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2353\/ajpath.2009.080561","volume":"174","author":"O Ovchinnikova","year":"2009","unstructured":"Ovchinnikova O, Robertson AK, W\u00e5gs\u00e4ter D, Folco EJ, Hyry M, Myllyharju J, et al. T-cell activation leads to reduced collagen maturation in atherosclerotic plaques of Apoe(-\/) mice. Am J Pathol. 2009;174(2):693\u2013700. https:\/\/doi.org\/10.2353\/ajpath.2009.080561.","journal-title":"Am J Pathol"},{"issue":"8","key":"1382_CR96","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1161\/ATVBAHA.109.189407","volume":"29","author":"Z Yang","year":"2009","unstructured":"Yang Z, Gagarin D, St Laurent G, Hammell N, Toma I, Hu C, et al. Cardiovascular inflammation and lesion cell apoptosis: a novel connection via the interferon-inducible immunoproteasome. Arterioscler Thromb Vasc Biol. 2009;29(8):1213\u20139. https:\/\/doi.org\/10.1161\/ATVBAHA.109.189407.","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"1382_CR97","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1161\/01.ATV.0000059419.11002.6E","volume":"23","author":"C Buono","year":"2003","unstructured":"Buono C, Come CE, Stavrakis G, Maguire GF, Connelly PW, Lichtman AH. Influence of interferon-\u03b3 on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse. Arterioscler Thromb Vasc Biol. 2003;23:454\u201360. https:\/\/doi.org\/10.1161\/01.ATV.0000059419.11002.6E.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1382_CR98","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1172\/JCI119465","volume":"99","author":"S Gupta","year":"1997","unstructured":"Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C. IFN-\u03b3 potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest. 1997;99:2752\u201361. https:\/\/doi.org\/10.1172\/JCI119465.","journal-title":"J Clin Invest."},{"key":"1382_CR99","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1172\/JCI119564","volume":"100","author":"H Nagano","year":"1997","unstructured":"Nagano H, Mitchell RN, Taylor MK, Hasegawa S, Tilney NL, Libby P. Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. J Clin Invest. 1997;100:550\u20137. https:\/\/doi.org\/10.1172\/JCI119564.","journal-title":"J Clin Invest"},{"key":"1382_CR100","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/s0002-9440(10)64820-1","volume":"157","author":"SC Whitman","year":"2000","unstructured":"Whitman SC, Ravisankar P, Elam H, Daugherty A. Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E\u2212\/\u2212 mice. Am J Pathol. 2000;157:1819\u201324. https:\/\/doi.org\/10.1016\/s0002-9440(10)64820-1.","journal-title":"Am J Pathol"},{"key":"1382_CR101","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1002\/acr.23171","volume":"69","author":"H Radner","year":"2017","unstructured":"Radner H, Lesperance T, Accortt NA, Solomon DH. Incidence and prevalence of cardiovascular risk factors among patients with rheumatoid arthritis, psoriasis, or psoriatic arthritis. Arthritis Care Res (Hoboken). 2017;69:1510\u20138. https:\/\/doi.org\/10.1002\/acr.23171.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1382_CR102","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.iac.2017.01.005","volume":"37","author":"RM Wolfe","year":"2017","unstructured":"Wolfe RM, Ang DC. Biologic therapies for autoimmune and connective tissue diseases. Immunol Allergy Clin North Am. 2017;37:283\u201399. https:\/\/doi.org\/10.1016\/j.iac.2017.01.005.","journal-title":"Immunol Allergy Clin North Am"},{"key":"1382_CR103","first-page":"227","volume":"9","author":"RE Schiotis","year":"2016","unstructured":"Schiotis RE, Buzoianu AD, Mure\u0219anu DF, Suciu S. New pharmacological strategies in rheumatic diseases. J Med Life. 2016;9:227\u201334.","journal-title":"J Med Life"},{"key":"1382_CR104","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1001\/archdermatol.2009.94","volume":"145","author":"S Prodanovich","year":"2009","unstructured":"Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol. 2009;145:700\u20133. https:\/\/doi.org\/10.1001\/archdermatol.2009.94.","journal-title":"Arch Dermatol"},{"key":"1382_CR105","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1365-2133.2006.07562.x","volume":"156","author":"RJ Ludwig","year":"2007","unstructured":"Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Zollner TM, Thaci D, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol. 2007;156:271\u20136. https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07562.x.","journal-title":"Br J Dermatol"},{"key":"1382_CR106","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","volume":"296","author":"JM Gelfand","year":"2006","unstructured":"Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735\u201341. https:\/\/doi.org\/10.1001\/jama.296.14.1735.","journal-title":"JAMA"},{"key":"1382_CR107","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3389\/fimmu.2018.00579","volume":"9","author":"WH Boehncke","year":"2018","unstructured":"Boehncke WH. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front Immunol. 2018;9:579. https:\/\/doi.org\/10.3389\/fimmu.2018.00579.","journal-title":"Front Immunol"},{"key":"1382_CR108","doi-asserted-by":"publisher","first-page":"13831","DOI":"10.1038\/s41598-017-14365-1","volume":"7","author":"NN Mehta","year":"2017","unstructured":"Mehta NN, Teague HL, Swindell WR, Baumer Y, Ward NL, Xing X, et al. IFN-\u03b3 and TNF-\u03b1 synergism may provide a link between psoriasis and inflammatory atherogenesis. Sci Rep. 2017;7:13831. https:\/\/doi.org\/10.1038\/s41598-017-14365-1.","journal-title":"Sci Rep"},{"key":"1382_CR109","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.autrev.2011.05.022","volume":"10","author":"R Ramonda","year":"2011","unstructured":"Ramonda R, Lo Nigro A, Modesti V, Nalotto L, Musacchio E, Iaccarino L, et al. Atherosclerosis in psoriatic arthritis. Autoimmun Rev. 2011;10:773\u20138. https:\/\/doi.org\/10.1016\/j.autrev.2011.05.022.","journal-title":"Autoimmun Rev"},{"key":"1382_CR110","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.3389\/fimmu.2019.01503","volume":"10","author":"I Bonaccorsi","year":"2019","unstructured":"Bonaccorsi I, Spinelli D, Cantoni C, Barill\u00e0 C, Pipit\u00f2 N, De Pasquale C, et al. Symptomatic carotid atherosclerotic plaques are associated with increased infiltration of natural killer (NK) cells and higher serum levels of NK activating receptor ligands. Front Immunol. 2019;10:1503. https:\/\/doi.org\/10.3389\/fimmu.2019.01503.","journal-title":"Front Immunol"},{"key":"1382_CR111","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.clim.2009.07.007","volume":"133","author":"KD Patel","year":"2009","unstructured":"Patel KD, Duggan SP, Currid CA, Gallagher WM, McManus R, Kelleher D, Murphy RT, Ryan AW. High sensitivity cytokine detection in acute coronary syndrome reveals up-regulation of interferon gamma and interleukin-10 post myocardial infarction. Clin Immunol. 2009;133:251\u201366. https:\/\/doi.org\/10.1016\/j.clim.2009.07.007.","journal-title":"Clin Immunol"},{"key":"1382_CR112","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.pcad.2008.09.001","volume":"5","author":"B Halvorsen","year":"2008","unstructured":"Halvorsen B, Otterdal K, Dahl TB, Skjelland M, Gullestad L, \u00d8ie E, et al. Atherosclerotic plaque stability\u2013what determines the fate of a plaque? Prog Cardiovasc Dis. 2008;5:183\u201394. https:\/\/doi.org\/10.1016\/j.pcad.2008.09.001.","journal-title":"Prog Cardiovasc Dis"},{"key":"1382_CR113","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1160\/TH08-07-0469","volume":"101","author":"AC Newby","year":"2009","unstructured":"Newby AC, George SJ, Ismail Y, Johnson JL, Sala-Newby GB, Thomas AC. Vulnerable atherosclerotic plaque metalloproteinases and foam cell phenotypes. Thromb Haemost. 2009;101:1006\u2013111.","journal-title":"Thromb Haemost"},{"key":"1382_CR114","doi-asserted-by":"publisher","first-page":"45406","DOI":"10.1074\/jbc.M309075200","volume":"278","author":"M Zhou","year":"2003","unstructured":"Zhou M, Zhang Y, Ardans JA, Wahl LM. Interferon-\u03b3 differentially regulates monocyte matrix metalloproteinase-1 and 9 through tumor necrosis factor-\u03b1 and caspase 8. J Biol Chem. 2003;278:45406\u201313. https:\/\/doi.org\/10.1074\/jbc.M309075200.","journal-title":"J Biol Chem"},{"key":"1382_CR115","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1186\/ar124","volume":"2","author":"JP Seery","year":"2000","unstructured":"Seery JP. IFN-gamma transgenic mice: clues to the pathogenesis of systemic lupus erythematosus? Arthritis Res. 2000;2:437\u201340. https:\/\/doi.org\/10.1186\/ar124.","journal-title":"Arthritis Res"},{"key":"1382_CR116","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.immuni.2012.10.010","volume":"37","author":"SK Lee","year":"2012","unstructured":"Lee SK, Silva DG, Martin JL, Pratama A, Hu X, Chang PP, et al. Interferon-gamma excess leads to pathogenic accumulation of follicular helper T cells and germinal centers. Immunity. 2012;37:880\u201392. https:\/\/doi.org\/10.1016\/j.immuni.2012.10.010.","journal-title":"Immunity"},{"key":"1382_CR117","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1172\/JCI750","volume":"101","author":"D Balomenos","year":"1998","unstructured":"Balomenos D, Rumold R, Theofilopoulos AN. Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J Clin Invest. 1998;101:364\u201371. https:\/\/doi.org\/10.1172\/JCI750.","journal-title":"J Clin Invest"},{"key":"1382_CR118","doi-asserted-by":"publisher","first-page":"456S","DOI":"10.1093\/ajcn\/83.2.456S","volume":"83","author":"P Libby","year":"2006","unstructured":"Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006;83:456S\u201360S. https:\/\/doi.org\/10.1093\/ajcn\/83.2.456S.","journal-title":"Am J Clin Nutr"},{"key":"1382_CR119","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrcardio.2016.185","volume":"14","author":"N Ruparelia","year":"2017","unstructured":"Ruparelia N, Chai JT, Fisher EA, Choudhury RP. Inflammatory processes in cardiovascular disease: a route to targeted therapies. Nat Rev Cardiol. 2017;14:133\u201344. https:\/\/doi.org\/10.1038\/nrcardio.2016.185.","journal-title":"Nat Rev Cardiol"},{"key":"1382_CR120","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2174\/157016106777698379","volume":"4","author":"K Schroecksnadel","year":"2006","unstructured":"Schroecksnadel K, Frick B, Winkler C, Fuchs D. Crucial role of interferon-gamma and stimulated macrophages in cardiovascular disease. Curr Vasc Pharmacol. 2006;4:205\u201313. https:\/\/doi.org\/10.2174\/157016106777698379.","journal-title":"Curr Vasc Pharmacol"},{"key":"1382_CR121","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1161\/01.cir.102.24.2919","volume":"102","author":"X Zhou","year":"2000","unstructured":"Zhou X, Nicoletti A, Elhage R, Hansson GK. Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation. 2000;102:2919\u201322. https:\/\/doi.org\/10.1161\/01.cir.102.24.2919.","journal-title":"Circulation"},{"key":"1382_CR122","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1161\/01.atv.15.11.1995","volume":"15","author":"YJ Geng","year":"1995","unstructured":"Geng YJ, Holm J, Nygren S, Bruzelius M, Stemme S, Hansson GK. Expression of macrophage scavenger receptor in atherosclerosis: relationship between scavenger receptor isoforms and the T cell cytokine, interferon-\u03b3. Arterioscler Thromb Vasc Biol. 1995;15:1995\u20132002. https:\/\/doi.org\/10.1161\/01.atv.15.11.1995.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1382_CR123","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s11481-014-9560-2","volume":"9","author":"HA Seifert","year":"2014","unstructured":"Seifert HA, Collier LA, Chapman CB, Benkovic SA, Willing AE, Pennypacker KR. Pro-inflammatory interferon gamma signaling is directly associated with stroke induced neurodegeneration. J Neuroimmune Pharmacol. 2014;9:679\u201389. https:\/\/doi.org\/10.1007\/s11481-014-9560-2.","journal-title":"J Neuroimmune Pharmacol"},{"key":"1382_CR124","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.acvd.2017.08.001","volume":"110","author":"J Joffre","year":"2017","unstructured":"Joffre J, Ait-Oufella H. Targeting the immune response in atherosclerosis: It's time for clinical trials! Arch Cardiovasc Dis. 2017;110:643\u20135. https:\/\/doi.org\/10.1016\/j.acvd.2017.08.001.","journal-title":"Arch Cardiovasc Dis"},{"key":"1382_CR125","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1371\/journal.pone.0151057","volume":"11","author":"JW Moss","year":"2016","unstructured":"Moss JW, Davies TS, Garaiova I, Plummer SF, Michael DR, Ramji DP. A Unique combination of nutritionally active ingredients can prevent several key processes associated with atherosclerosis in vitro. PLoS ONE. 2016;11:1057. https:\/\/doi.org\/10.1371\/journal.pone.0151057.","journal-title":"PLoS ONE"},{"key":"1382_CR126","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.atherosclerosis.2016.01.026","volume":"246","author":"MC Boshuizen","year":"2016","unstructured":"Boshuizen MC, Neele AE, Gijbels MJ, van der Velden S, Hoeksema MA, Forman RA, et al. Myeloid interferon-\u03b3 receptor deficiency does not affect atherosclerosis in LDLR\u2212\/\u2212 mice. Atherosclerosis. 2016;246:325\u201333. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.01.026.","journal-title":"Atherosclerosis"},{"key":"1382_CR127","doi-asserted-by":"publisher","first-page":"E3534","DOI":"10.3390\/ijms20143534","volume":"20","author":"LW Chen","year":"2019","unstructured":"Chen LW, Lin CS, Tsai MC, Shih SF, Lim ZW, Chen SJ, et al. Pitavastatin exerts potent anti-inflammatory and immunomodulatory effects via the suppression of AP-1 signal transduction in human T cells. Int J Mol Sci. 2019;20:E3534. https:\/\/doi.org\/10.3390\/ijms20143534.","journal-title":"Int J Mol Sci."},{"key":"1382_CR128","doi-asserted-by":"publisher","first-page":"17529","DOI":"10.18632\/oncotarget.15420","volume":"8","author":"A Severino","year":"2017","unstructured":"Severino A, Zara C, Campioni M, Flego D, Angelini G, Pedicino D, et al. Atorvastatin inhibits the immediate-early response gene EGR1 and improves the functional profile of CD4+T-lymphocytes in acute coronary syndromes. Oncotarget. 2017;8:17529\u201350. https:\/\/doi.org\/10.18632\/oncotarget.15420.","journal-title":"Oncotarget"},{"key":"1382_CR129","doi-asserted-by":"publisher","first-page":"131530","DOI":"10.1172\/jci.insight.131530","volume":"4","author":"PW Karmaus","year":"2019","unstructured":"Karmaus PW, Shi M, Perl S, Biancotto A, Candia J, Cheung F, et al. Effects of rosuvastatin on the immune system in healthy volunteers with normal serum cholesterol. JCI Insight. 2019;4:131530. https:\/\/doi.org\/10.1172\/jci.insight.131530.","journal-title":"JCI Insight."},{"key":"1382_CR130","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1365-2796.2011.02394.x","volume":"271","author":"R Krysiak","year":"2012","unstructured":"Krysiak R, Zmuda W, Okopien B. The effect of ezetimibe, administered alone or in combination with simvastatin, on lymphocyte cytokine release in patients with elevated cholesterol levels. J Intern Med. 2012;271:32\u201342. https:\/\/doi.org\/10.1111\/j.1365-2796.2011.02394.x.","journal-title":"J Intern Med"},{"key":"1382_CR131","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.atherosclerosis.2011.04.018","volume":"216","author":"B Cariou","year":"2011","unstructured":"Cariou B, Le May C, Costet P. Clinical aspects of PCSK9. Atherosclerosis. 2011;216:258\u201365. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.04.018.","journal-title":"Atherosclerosis"},{"key":"1382_CR132","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1042\/CS20180190","volume":"132","author":"AB Reiss","year":"2018","unstructured":"Reiss AB, Shah N, Muhieddine D, Zhen J, Yudkevich J, Kasselman LJ, et al. PCSK9 in cholesterol metabolism: from bench to bedside. Clin Sci (Lond). 2018;132:1135\u201353. https:\/\/doi.org\/10.1042\/CS20180190.","journal-title":"Clin Sci (Lond)"},{"key":"1382_CR133","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12916-019-1457-8","volume":"17","author":"AA Momtazi-Borojeni","year":"2019","unstructured":"Momtazi-Borojeni AA, Jaafari MR, Badiee A, Banach M, Sahebkar A. Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis. BMC Med. 2019;17:223. https:\/\/doi.org\/10.1186\/s12916-019-1457-8.","journal-title":"BMC Med"},{"key":"1382_CR134","doi-asserted-by":"publisher","first-page":"e0191895","DOI":"10.1371\/journal.pone.0191895","volume":"13","author":"R Kawakami","year":"2018","unstructured":"Kawakami R, Nozato Y, Nakagami H, Ikeda Y, Shimamura M, Yoshida S, et al. Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin\/kexin type 9 (PCSK9) epitope in mice. PLoS ONE. 2018;13:e0191895. https:\/\/doi.org\/10.1371\/journal.pone.0191895.","journal-title":"PLoS ONE"},{"key":"1382_CR135","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1291\/hypres.30.259","volume":"30","author":"M Koga","year":"2007","unstructured":"Koga M, Kai H, Yasukawa H, Kato S, Yamamoto T, Kawai Y, et al. Postnatal blocking of interferon-gamma function prevented atherosclerotic plaque formation in apolipoprotein E-knockout mice. Hypertens Res. 2007;30:259\u201367. https:\/\/doi.org\/10.1291\/hypres.30.259.","journal-title":"Hypertens Res"},{"issue":"4","key":"1382_CR136","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1161\/CIRCRESAHA.106.147256","volume":"101","author":"M Koga","year":"2007","unstructured":"Koga M, Kai H, Yasukawa H, Yamamoto T, Kawai Y, et al. Inhibition of progression and stabilization of plaques by postnatal interferon-gamma function blocking in ApoE-knockout mice. Circ Res. 2007;101(4):348\u201356. https:\/\/doi.org\/10.1161\/CIRCRESAHA.106.147256.","journal-title":"Circ Res"},{"key":"1382_CR137","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1161\/CIRCRESAHA.115.306932","volume":"117","author":"J Zhou","year":"2015","unstructured":"Zhou J, Qin L, Yi T, Ali R, Li Q, Jiao Y, et al. Interferon-\u03b3-mediated allograft rejection exacerbates cardiovascular disease of hyperlipidemic murine transplant recipients. Circ Res. 2015;117:943\u201355. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.306932.","journal-title":"Circ Res"},{"key":"1382_CR138","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.gtc.2014.05.008","volume":"43","author":"S Singh","year":"2014","unstructured":"Singh S, Pardi DS. Update on anti-tumor necrosis factor agents in Crohn disease. Gastroenterol Clin North Am. 2014;43:457\u201378. https:\/\/doi.org\/10.1016\/j.gtc.2014.05.008.","journal-title":"Gastroenterol Clin North Am"},{"key":"1382_CR139","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1080\/14740338.2019.1663168","volume":"18","author":"S D'Adamio","year":"2019","unstructured":"D'Adamio S, Silvaggio D, Lombardo P, Bianchi L, Talamonti M, Galluzzo M. The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis. Expert Opin Drug Saf. 2019;18:1031\u201341. https:\/\/doi.org\/10.1080\/14740338.2019.1663168.","journal-title":"Expert Opin Drug Saf"},{"key":"1382_CR140","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/ibd.21038","volume":"16","author":"W Reinisch","year":"2010","unstructured":"Reinisch W, de Villiers W, Bene L, Simon L, R\u00e1cz I, Katz S, Altorjay I, Feagan B, Riff D, Bernstein CN, Hommes D, Rutgeerts P, Cortot A, Gaspari M, Cheng M, Pearce T, Sands BE. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis. 2010;16:233\u201342. https:\/\/doi.org\/10.1002\/ibd.21038.","journal-title":"Inflamm Bowel Dis"},{"issue":"374\u2013388","key":"1382_CR141","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1053\/j.gastro.2016.10.018","volume":"152","author":"C Abraham","year":"2017","unstructured":"Abraham C, Dulai PS, Vermeire S, Sandborn WJ. Lessons learned from trials targeting cytokine pathways in patients with inflammatory bowel diseases. Gastroenterology. 2017;152(374\u2013388):e4. https:\/\/doi.org\/10.1053\/j.gastro.2016.10.018.","journal-title":"Gastroenterology"},{"key":"1382_CR142","doi-asserted-by":"publisher","first-page":"e000226","DOI":"10.1136\/lupus-2017-000226","volume":"4","author":"MJ Boedigheimer","year":"2017","unstructured":"Boedigheimer MJ, Martin DA, Amoura Z, S\u00e1nchez-Guerrero J, Romero-Diaz J, Kivitz A, et al. Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-\u03b3 monoclonal antibody, in SLE subjects without or with lupus nephritis. Lupus Sci Med. 2017;4:e000226. https:\/\/doi.org\/10.1136\/lupus-2017-000226.","journal-title":"Lupus Sci Med"},{"key":"1382_CR143","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1161\/CIRCRESAHA.107.155838","volume":"101","author":"I Gotsman","year":"2007","unstructured":"Gotsman I, Lichtman AH. Targeting interferon-gamma to treat atherosclerosis. Circ Res. 2007;101:333\u20134. https:\/\/doi.org\/10.1161\/CIRCRESAHA.107.155838.","journal-title":"Circ Res"},{"key":"1382_CR144","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1146\/annurev-immunol-032713-120222","volume":"32","author":"SK Browne","year":"2014","unstructured":"Browne SK. Anticytokine autoantibody\u2013associated immunodeficiency. Annu Rev Immunol. 2014;32:635\u201357. https:\/\/doi.org\/10.1146\/annurev-immunol-032713-120222.","journal-title":"Annu Rev Immunol"},{"key":"1382_CR145","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.4161\/15548627.2014.981791","volume":"10","author":"AI Rovetta","year":"2014","unstructured":"Rovetta AI, Pe\u00f1a D, Hern\u00e1ndez Del Pino RE, Recalde GM, Pellegrini J, Bigi F, et al. IFNG-mediated immune responses enhance autophagy against mycobacterium tuberculosis antigens in patients with active tuberculosis. Autophagy. 2014;10:2109\u201321. https:\/\/doi.org\/10.4161\/15548627.2014.981791.","journal-title":"Autophagy"},{"key":"1382_CR146","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1515\/bmc-2018-0007","volume":"9","author":"G Kak","year":"2018","unstructured":"Kak G, Raza M, Tiwari BK. Interferon-gamma (IFN-\u03b3): Exploring its implications in infectious diseases. Biomol Concepts. 2018;9:64\u201379. https:\/\/doi.org\/10.1515\/bmc-2018-0007.","journal-title":"Biomol Concepts"},{"key":"1382_CR147","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3389\/fnins.2015.00287","volume":"9","author":"NM Miller","year":"2015","unstructured":"Miller NM, Wang J, Tan Y, Dittel BN. Anti-inflammatory mechanisms of IFN-\u03b3 studied in experimental autoimmune encephalomyelitis reveal neutrophils as a potential target in multiple sclerosis. Front Neurosci. 2015;9:287. https:\/\/doi.org\/10.3389\/fnins.2015.00287.","journal-title":"Front Neurosci"},{"key":"1382_CR148","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/S1567-5769(03)00131-0","volume":"3","author":"H M\u00fchl","year":"2003","unstructured":"M\u00fchl H, Pfeilschifter J. Anti-inflammatory properties of pro-inflammatory interferon-\u03b3. Int Immunopharmacol. 2003;3:1247\u201355. https:\/\/doi.org\/10.1016\/S1567-5769(03)00131-0.","journal-title":"Int Immunopharmacol"},{"key":"1382_CR149","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1177\/0394632015595757","volume":"28","author":"SH Venkatesha","year":"2015","unstructured":"Venkatesha SH, Dudics S, Weingartner E, So EC, Pedra J, Moudgil KD. Altered Th17\/Treg balance and dysregulated IL-1\u03b2 response influence susceptibility\/resistance to experimental autoimmune arthritis. Int J Immunopathol Pharmacol. 2015;28:318\u201328. https:\/\/doi.org\/10.1177\/0394632015595757.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"1382_CR150","doi-asserted-by":"publisher","first-page":"5298","DOI":"10.4049\/jimmunol.0902819","volume":"184","author":"JS Fridman","year":"2010","unstructured":"Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, et al. Selective inhibition of jak1 and jak2 is efficacious in rodent models of arthritis: Preclinical characterization of incb028050. J Immunol. 2010;184:5298\u2013307. https:\/\/doi.org\/10.4049\/jimmunol.0902819.","journal-title":"J Immunol"},{"key":"1382_CR151","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s40744-018-0128-0","volume":"5","author":"R Van Vollenhoven","year":"2018","unstructured":"Van Vollenhoven R, Helt C, Arora V, Zhong J, Correia AP, de la Torre I, et al. Safety and efficacy of baricitinib in patients receiving conventional synthetic disease-modifying antirheumatic drugs or corticosteroids. Rheumatol Ther. 2018;5:525\u201336. https:\/\/doi.org\/10.1007\/s40744-018-0128-0.","journal-title":"Rheumatol Ther"},{"key":"1382_CR152","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1136\/annrheumdis-2018-214846","volume":"78","author":"W Xie","year":"2019","unstructured":"Xie W, Huang Y, Xiao S, Sun X, Fan Y, Zhang Z. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis. 2019;78:1048\u201354. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214846.","journal-title":"Ann Rheum Dis"},{"key":"1382_CR153","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/art.40841","volume":"71","author":"PC Taylor","year":"2019","unstructured":"Taylor PC, Weinblatt ME, Burmester GR, Rooney TP, Witt S, Walls CD, et al. Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis. Arthritis Rheumatol. 2019;71:1042\u201355. https:\/\/doi.org\/10.1002\/art.40841.","journal-title":"Arthritis Rheumatol"},{"key":"1382_CR154","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12944-019-0994-7","volume":"18","author":"C Qiu","year":"2019","unstructured":"Qiu C, Zhao X, She L, Shi Z, Deng Z, Tan L, et al. Baricitinib induces LDL-C and HDL-C increases in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Lipids Health Dis. 2019;18:54. https:\/\/doi.org\/10.1186\/s12944-019-0994-7.","journal-title":"Lipids Health Dis"},{"key":"1382_CR155","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X19895492","author":"W Xie","year":"2019","unstructured":"Xie W, Xiao S, Huang Y, Sun X, Zhang Z. Effect of tofacitinib on cardiovascular events and all-cause mortality in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials. Ther Adv Musculoskelet Dis. 2019. https:\/\/doi.org\/10.1177\/1759720X19895492.","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"1382_CR156","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s40264-020-00904-9","volume":"40","author":"GR Burmester","year":"2020","unstructured":"Burmester GR, Curtis JR, Yun H, FitzGerald O, Winthrop KL, Azevedo VF, et al. An integrated analysis of the safety of tofacitinib in psoriatic arthritis across phase III and long-term extension studies with comparison to real-world observational data. Drug Saf. 2020;40:379\u201392. https:\/\/doi.org\/10.1007\/s40264-020-00904-9.","journal-title":"Drug Saf"},{"issue":"5","key":"1382_CR157","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s40256-019-00345-5","volume":"19","author":"AB Reiss","year":"2019","unstructured":"Reiss AB, Grossfeld D, Kasselman LJ, Renna HA, Vernice NA, Drewes W, Konig J, Carsons SE, DeLeon J. Adenosine and the cardiovascular system. Am J Cardiovasc Drugs. 2019;19(5):449\u201364. https:\/\/doi.org\/10.1007\/s40256-019-00345-5.","journal-title":"Am J Cardiovasc Drugs"},{"key":"1382_CR158","doi-asserted-by":"publisher","first-page":"6767","DOI":"10.4049\/jimmunol.0900331","volume":"183","author":"KE Barnholt","year":"2009","unstructured":"Barnholt KE, Kota RS, Aung HH, Rutledge JC. Adenosine blocks IFN-gamma-induced phosphorylation of STAT1 on serine 727 to reduce macrophage activation. J Immunol. 2009;183:6767\u201377. https:\/\/doi.org\/10.4049\/jimmunol.0900331.","journal-title":"J Immunol"},{"key":"1382_CR159","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/708746","author":"S Cohen","year":"2014","unstructured":"Cohen S, Barer F, Bar-Yehuda S, Ijzerman AP, Jacobson KA, Fishman P. A3 adenosine receptor allosteric modulator induces an anti-inflammatory effect: in vivo studies and molecular mechanism of action. Mediators Inflamm. 2014. https:\/\/doi.org\/10.1155\/2014\/708746.","journal-title":"Mediators Inflamm."},{"key":"1382_CR160","doi-asserted-by":"publisher","first-page":"969","DOI":"10.2174\/1381612825666190430113212","volume":"25","author":"AB Reiss","year":"2019","unstructured":"Reiss AB, Silverman A, Khalfan M, Vernice NA, Kasselman LJ, Carsons SE, et al. Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte\/macrophages. Curr Pharm Des. 2019;25:969\u201386. https:\/\/doi.org\/10.2174\/1381612825666190430113212.","journal-title":"Curr Pharm Des"},{"key":"1382_CR161","doi-asserted-by":"publisher","first-page":"503028","DOI":"10.1155\/2011\/503028","volume":"2011","author":"E Coomes","year":"2011","unstructured":"Coomes E, Chan ES, Reiss AB. Methotrexate in atherogenesis and cholesterol metabolism. Cholesterol. 2011;2011:503028. https:\/\/doi.org\/10.1155\/2011\/503028.","journal-title":"Cholesterol"},{"key":"1382_CR162","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1056\/NEJMoa1809798","volume":"380","author":"PM Ridker","year":"2019","unstructured":"Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, et al. CIRT Investigators Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med. 2019;380:752\u201362. https:\/\/doi.org\/10.1056\/NEJMoa1809798.","journal-title":"N Engl J Med."},{"key":"1382_CR163","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1177\/1535370216647181","volume":"241","author":"I Voloshyna","year":"2016","unstructured":"Voloshyna I, Teboul I, Littlefield MJ, Siegart NM, Turi GK, Fazzari MJ, et al. Resveratrol counters systemic lupus erythematosus-associated atherogenicity by normalizing cholesterol efflux. Exp Biol Med (Maywood). 2016;241:1611\u20139. https:\/\/doi.org\/10.1177\/1535370216647181.","journal-title":"Exp Biol Med (Maywood)"},{"key":"1382_CR164","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ejphar.2012.08.024","volume":"698","author":"I Voloshyna","year":"2013","unstructured":"Voloshyna I, Hai O, Littlefield MJ, Carsons S, Reiss AB. Resveratrol mediates anti-atherogenic effects on cholesterol flux in human macrophages and endothelium via PPAR\u03b3 and adenosine. Eur J Pharmacol. 2013;698:299\u2013309. https:\/\/doi.org\/10.1016\/j.ejphar.2012.08.024.","journal-title":"Eur J Pharmacol"},{"key":"1382_CR165","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/j.jnutbio.2010.07.012","volume":"22","author":"EY Chung","year":"2011","unstructured":"Chung EY, Kim BH, Hong JT, Lee CK, Ahn B, Nam SY, Han SB, et al. Resveratrol down-regulates interferon-\u03b3-inducible inflammatory genes in macrophages: molecular mechanism via decreased STAT-1 activation. J Nutr Biochem. 2011;22:902\u20139. https:\/\/doi.org\/10.1016\/j.jnutbio.2010.07.012.","journal-title":"J Nutr Biochem"},{"key":"1382_CR166","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1002\/mnfr.201500166","volume":"59","author":"LQ Trung","year":"2015","unstructured":"Trung LQ, Espinoza JL, An DT, Viet NH, Shimoda K, Nakao S. Resveratrol selectively induces apoptosis in malignant cells with the JAK2V617F mutation by inhibiting the JAK2 pathway. Mol Nutr Food Res. 2015;59:2143\u201354. https:\/\/doi.org\/10.1002\/mnfr.201500166.","journal-title":"Mol Nutr Food Res"},{"key":"1382_CR167","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/med.21565","volume":"39","author":"AP Singh","year":"2019","unstructured":"Singh AP, Singh R, Verma SS, Rai V, Kaschula CH, Maiti P, Gupta SC. Health benefits of resveratrol: evidence from clinical studies. Med Res Rev. 2019;39:1851\u201391. https:\/\/doi.org\/10.1002\/med.21565.","journal-title":"Med Res Rev"},{"key":"1382_CR168","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2174\/1871529X18666180103124443","volume":"17","author":"AB Reiss","year":"2017","unstructured":"Reiss AB, Vernice NA, Siegart NM, De Leon J, Kasselman LJ. Exosomes in cholesterol metabolism and atherosclerosis. Cardiovasc Hematol Disord Drug Targets. 2017;17:185\u201394. https:\/\/doi.org\/10.2174\/1871529X18666180103124443.","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"1382_CR169","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/ncb0309-228","volume":"11","author":"J Winter","year":"2009","unstructured":"Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol. 2009;11:228\u201334. https:\/\/doi.org\/10.1038\/ncb0309-228.","journal-title":"Nat Cell Biol"},{"key":"1382_CR170","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3389\/fimmu.2018.00293","volume":"9","author":"H Wang","year":"2018","unstructured":"Wang H, Zhang Y, Wu X, Wang Y, Cui H, Li X, et al. Regulation of human natural killer cell IFN-\u03b3 production by microRNA-146a via targeting the NF-\u03baB signaling pathway. Front Immunol. 2018;9:293. https:\/\/doi.org\/10.3389\/fimmu.2018.00293.","journal-title":"Front Immunol"},{"key":"1382_CR171","doi-asserted-by":"publisher","first-page":"21789","DOI":"10.1038\/srep21789","volume":"6","author":"X Li","year":"2016","unstructured":"Li X, Kong D, Chen H, Liu S, Hu H, Wu T, Wang J, Chen W, Ning Y, Li Y, Lu Z. miR-155 acts as an anti-inflammatory factor in atherosclerosis-associated foam cell formation by repressing calcium-regulated heat stable protein 1. Sci Rep. 2016;6:21789. https:\/\/doi.org\/10.1038\/srep21789.","journal-title":"Sci Rep"},{"key":"1382_CR172","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1172\/jci61716","volume":"122","author":"M Nazari-Jahantigh","year":"2012","unstructured":"Nazari-Jahantigh M, Wei Y, Noels H, Akhtar S, Zhou Z, Koenen RR, et al. MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages. J Clin Invest. 2012;122:4190\u2013202. https:\/\/doi.org\/10.1172\/jci61716.","journal-title":"J Clin Invest"},{"key":"1382_CR173","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.numecd.2018.06.017","volume":"28","author":"S Li","year":"2018","unstructured":"Li S, Sun Y, Zhong L, Xiao Z, Yang M, Chen M, et al. The suppression of ox-LDL-induced inflammatory cytokine release and apoptosis of HCAECs by long non-coding RNA-MALAT1 via regulating microRNA-155\/SOCS1 pathway. Nutr Metab Cardiovasc Dis. 2018;28:1175\u201387. https:\/\/doi.org\/10.1016\/j.numecd.2018.06.017.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"6","key":"1382_CR174","doi-asserted-by":"publisher","first-page":"E226","DOI":"10.3390\/biom9060226","volume":"9","author":"D Skuratovskaia","year":"2019","unstructured":"Skuratovskaia D, Vulf M, Komar A, Kirienkova E, Litvinova L. Promising directions in atherosclerosis treatment based on epigenetic regulation using microRNAs and long noncoding RNAs. Biomolecules. 2019;9(6):E226. https:\/\/doi.org\/10.3390\/biom9060226.","journal-title":"Biomolecules."},{"key":"1382_CR175","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1172\/JCI62876","volume":"123","author":"D Quiat","year":"2013","unstructured":"Quiat D, Olson EN. MicroRNAs in cardiovascular disease: from pathogenesis to prevention and treatment. J Clin Invest. 2013;123:11\u20138. https:\/\/doi.org\/10.1172\/JCI62876.","journal-title":"J Clin Invest"},{"key":"1382_CR176","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1161\/CIRCRESAHA","volume":"110","author":"EE Creemers","year":"2012","unstructured":"Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res. 2012;110:483\u201395. https:\/\/doi.org\/10.1161\/CIRCRESAHA.","journal-title":"Circ Res"},{"key":"1382_CR177","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fgene.2019.00123","volume":"10","author":"CH Wang","year":"2019","unstructured":"Wang CH, Shi HH, Chen LH, Li XL, Cao GL, Hu XF. Identification of key lncRNAs associated with atherosclerosis progression based on public datasets. Front Genet. 2019;10:123. https:\/\/doi.org\/10.3389\/fgene.2019.00123.","journal-title":"Front Genet"},{"key":"1382_CR178","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.imbio.2018.03.002","volume":"223","author":"H Prebble","year":"2018","unstructured":"Prebble H, Cross S, Marks E, Healy J, Searle E, Aamir R, et al. Induced macrophage activation in live excised atherosclerotic plaque. Immunobiology. 2018;223:526\u201335. https:\/\/doi.org\/10.1016\/j.imbio.2018.03.002.","journal-title":"Immunobiology"},{"issue":"3","key":"1382_CR179","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1093\/hmg\/ddp507","volume":"19","author":"XF Kong","year":"2010","unstructured":"Kong XF, Vogt G, Chapgier A, et al. A novel form of cell type-specific partial IFN-gammaR1 deficiency caused by a germ line mutation of the IFNGR1 initiation codon. Hum Mol Genet. 2010;19(3):434\u201344. https:\/\/doi.org\/10.1093\/hmg\/ddp507.","journal-title":"Hum Mol Genet"},{"key":"1382_CR180","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3389\/fcell.2020.00321","volume":"8","author":"E L\u00f3pez","year":"2020","unstructured":"L\u00f3pez E, Marinaro F, de Pedro ML\u00c1, et al. The immunomodulatory signature of extracellular vesicles from cardiosphere-derived cells: a proteomic and miRNA profiling. Front Cell Dev Biol. 2020;8:321. https:\/\/doi.org\/10.3389\/fcell.2020.00321.","journal-title":"Front Cell Dev Biol"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-020-01382-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-020-01382-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-020-01382-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T23:05:07Z","timestamp":1626908707000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-020-01382-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,22]]},"references-count":180,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["1382"],"URL":"https:\/\/doi.org\/10.1007\/s00011-020-01382-6","relation":{},"ISSN":["1023-3830","1420-908X"],"issn-type":[{"value":"1023-3830","type":"print"},{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,22]]},"assertion":[{"value":"6 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"No ethics approval was required for this review that did not involve patients or patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}